Neurogene (NGNE) Accumulated Expenses (2013 - 2026)

Neurogene (NGNE) has 14 years of Accumulated Expenses data on file, last reported at $11.1 million in Q1 2026.

• Quarterly Accumulated Expenses rose 62.56% year-over-year to $11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (up 62.56% YoY) and the FY2025 annual result came in at $10.8 million, up 10.53% from the prior year.
• Accumulated Expenses advanced to $11.1 million in Q1 2026, from $10.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $17.5 million in Q4 2023 to a low of $5.3 million in Q4 2022.
• A 5-year average of $9.5 million and a median of $9.4 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 228.61% — and 2024, when it tumbled 44.38%.
• Tracing NGNE's Accumulated Expenses over 5 years: stood at $5.3 million in 2022, then surged by 228.61% to $17.5 million in 2023, then plunged by 44.38% to $9.7 million in 2024, then gained by 10.53% to $10.8 million in 2025, then increased by 3.51% to $11.1 million in 2026.
• The last three Accumulated Expenses figures came in at $11.1 million (Q1 2026), $10.8 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.